Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Dividend Yield | Payout Ratio | Last Dividend | Annual Dividend | Dividend Percentile | Dividend Dropped Count (L10Y) | Ex-dividend Date | Div. Payment Date |
|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BEONE MEDICINES LTD | $35.48B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| NVO | NOVO NORDISK A S | $244.88B | 1.99% | 30.60% | $1.0992 | $1.10 | 44% | 10 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $52.56B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $3.11B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $469.52M | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| CORT | CORCEPT THERAPEUTICS INC | $3.68B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| VCEL | VERICEL CORP | $1.88B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| ARGX | ARGENX SE | $48.88B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| KRYS | KRYSTAL BIOTECH INC | $7.10B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| TECH | BIO-TECHNE CORP | $9.82B | 0.51% | 64.00% | $0.0800 | $0.32 | 10% | 1 | ||
| GMAB | GENMAB A | $20.42B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| ABEO | ABEONA THERAPEUTICS INC | $282.88M | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| ADMA | ADMA BIOLOGICS INC | $4.29B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| XOMA | XOMA ROYALTY CORP | $329.64M | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $2.02B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| VCYT | VERACYTE INC | $3.45B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| LGND | LIGAND PHARMACEUTICALS INC | $3.78B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| CRMD | CORMEDIX INC | $960.44M | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| MNKD | MANNKIND CORP | $1.73B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| NAGE | NIAGEN BIOSCIENCE INC | $514.75M | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| RPRX | ROYALTY PHARMA PLC | $22.89B | 2.22% | 49.40% | $0.2200 | $0.88 | 49% | 0 | ||
| EXEL | EXELIXIS INC | $11.37B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $113.87B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $143.95M | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.31B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| APLS | APELLIS PHARMACEUTICALS INC | $3.15B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| HALO | HALOZYME THERAPEUTICS INC | $8.37B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.12B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.80B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| REGN | REGENERON PHARMACEUTICALS INC | $80.22B | 0.46% | 6.10% | $0.8800 | $3.52 | 9% | 0 | ||
| MDXG | MIMEDX GROUP INC | $937.49M | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| INVA | INNOVIVA INC | $1.50B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| UTHR | UNITED THERAPEUTICS CORP | $21.08B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| ACAD | ACADIA PHARMACEUTICALS INC | $4.42B | N/A | 0.00% | N/A | N/A | N/A | N/A | ||
| INCY | INCYTE CORP | $19.98B | N/A | 0.00% | N/A | N/A | N/A | N/A |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.